Gene Symbol | AFP |
---|---|
Entrez Gene | 174 |
Alt Symbol | AFPD, FETA, HPAFP |
Species | Human |
Gene Type | protein-coding |
Description | alpha-fetoprotein |
Other Description | alpha-1-fetoprotein|alpha-fetoglobulin |
Swissprots | P02771 B2RBU3 |
Accessions | AAA51674 AAA51675 AAB58754 CAA79592 EAX05681 P02771 AF484525 AF484526 AI336986 AK297669 BAG60031 AK297674 BAG60036 AK314817 BAG37340 BC027881 AAH27881 DQ890942 ABM81868 DQ894103 ABM85029 V01514 CAA24758 XM_011531704 XP_011530006 NM_001134 NP_001125 |
Function | Binds copper, nickel, and fatty acids as well as, and bilirubin less well than, serum albumin. Only a small percentage (less than 2%) of the human AFP shows estrogen-binding properties. |
Subcellular Location | Secreted. |
Tissue Specificity | Plasma. Synthesized by the fetal liver and yolk sac. |
Top Pathways | Hippo signaling pathway |
AFP-Over-expression-Lysate - LY10800a from Abgent, a WuXi AppTec company
|
||||||||
AFP 293T Cell Transient Overexpression Lysate(Denatured) - H00000174-T01 from Acris Antibodies
|
||||||||
AFP HEK293 Cell Transient Overexpression Lysate (Non-Denatured) - L006T6 from Acris Antibodies
|
||||||||
AFP overexpression lysate - LY400455 from Acris Antibodies
|
||||||||
AFP 293 Cell Lysate - 400465 from ABBIOTEC
|
||||||||
alpha-Fetoprotein/AFP Overexpression Lysate (Denatured) - H00000174-T01 from Novus Biologicals
|
||||||||
alpha-Fetoprotein/AFP Overexpression Lysate (Native) - NBL1-07375 from Novus Biologicals
|
||||||||
AFP (h): 293T Lysate - sc-114125 from Santa Cruz Biotechnology
|
||||||||
AFP (h2): 293T Lysate - sc-170237 from Santa Cruz Biotechnology
|
||||||||
AFP Over-expression Lysate Product - GWB-536D51 from Genway Biotech
|
||||||||
Human AFP / alpha-fetoprotein HEK293 Cell Lysate (WB positive control) - 12177-H08HL-300 from Sino Biological
|
||||||||
Human Alpha 1 Fetoprotein Human Cells Transfected Lysate (positive control) (denatured) - orb174006 from Biorbyt
|
||||||||
Panoply™ Human AFP Knockdown Stable Cell Line - CSC-DC000355 from Creative biogene
|
||||||||